OBJECTIVES: Surgical aortic valve replacement in patients with previous coronary artery bypass grafting (CABG) carries a high mortality. Transcatheter aortic valve implantation (TAVI) has been shown to be successful in high risk subgroups of patients. Our goal is therefore to evaluate the impact of a history of CABG on the outcome of patients who undergo TAVI.
INTRODUCTION
Severe aortic stenosis (AS) in patients with previous coronary artery bypass grafting (CABG) is a common clinical problem. In this case, redo aortic valve replacement (AVR) is indicated but carries a high risk [1] [2] [3] [4] . Transcatheter aortic valve implantation (TAVI) has therefore been suggested as an alternative to surgery in this high-risk group of patients [5] . However, to the best of our knowledge, no study has specifically evaluated patients with previous CABG undergoing TAVI. Our goal was therefore to evaluate the impact of a history of CABG on the outcome of patients who undergo TAVI.
MATERIALS AND METHODS

Patients
From October 2006 to June 2010, all high-risk patients with severe symptomatic AS evaluated for TAVI in our institution underwent multidisciplinary evaluation by a heart team. The algorithm for management of those patients has been previously described [6] . Briefly, the decision to perform TAVI was taken in patients with contraindications to, or at high risk for AVR [7, 8] , and with anatomy suitable for TAVI [5] . Patients with a history of previous CABG were considered at high risk for surgery and this gave a further incentive for TAVI. Comorbidities were evaluated using the Charlson comorbidity index [9] .
Coronary angiography was systematically performed as a screening test. Significant coronary stenosis was defined as ≥70% luminal diameter narrowing of an epicardial artery measured in the 'worst view' angiographic projection (≥50% for left main stem).
Baseline characteristics were prospectively collected. In addition, for the patients with previous CABG we specifically recorded date, number and type of grafts (mammary vs. saphenous vein graft); as well as number and type of patent grafts at the time of TAVI.
TAVI procedure
The technical aspects of the procedure have been described elsewhere [6] . The transfemoral approach was considered as the first option, and transapical, subclavian or transiliac alternatives were used in patients with contraindications to the transfemoral approach. From October 2006 to May 2008, the Edwards Sapien was the only prosthesis used. From May 2008, the Medtronic Corevalve® System was also used according to the anatomical characteristics of patients [6] .
Follow-up
All clinical events were prospectively recorded during the hospital stay and follow-up. Clinical and transthoracic echocardiography follow-up were obtained in all survivors at 1 month, 6 months, 1 year, and then annually.
Outcomes
Implantation success was defined as valve implantation in the correct position. All cause mortality was considered when reporting 30-day and mid-term mortality. Troponin I was measured within the first 24 hr after TAVI. All electrocardiograms were recorded before and after the procedure. Periprocedural myocardial infarction (MI) was defined as an increase in troponin of more than five times the 99th percentile upper range limit (URL) associated with new ischaemic signs (e.g. chest pain or shortness of breath, ventricular arrhythmias, new or worsening heart failure, new ST-segment changes, haemodynamic instability, or imaging evidence of new loss of viable myocardium or new wall motion abnormality). Stroke was defined as a rapid onset of a focal or global neurological deficit confirmed by a magnetic resonance imaging or a computed tomography scan. Severe bleeding was defined as bleeding in a critical organ area or causing death or any overt bleeding requiring packed red blood cell transfusion. Major vascular complications were defined as any aortic dissection or access-related vascular injury leading to either death, need for significant blood transfusion (≥4 units), unplanned intervention or irreversible end organ damage.
Statistical analysis
Quantitative variables were expressed as mean ± standard deviation or median and interquartile ranges [25-75th percentiles]. Inter-group comparisons were performed using the unpaired Student t-test, the Mann-Whitney U test, or the χ 2 test as appropriate. Cumulative survival curves were determined according to the Kaplan-Meier method. Univariate analysis of the predictive factors of in-hospital mortality used the unpaired Student t-test or the χ 2 test, where appropriate. Univariate analysis of the predictive factors of late mortality was performed using a Cox univariate model. To evaluate the effect of experience on mid-term outcome, we compared the first 25 procedures with the 26-201st procedures.
Variables with P < 0.20 in univariate analysis were entered in a multivariate Cox proportional hazards model and were selected by a backward procedure with a threshold of P = 0.05, except for the Charlson comorbidity index which was forced in the model. All analyses were performed with SAS statistical software (SAS Institute Inc.). All tests were two-sided. A P-value < 0.05 was considered significant.
RESULTS
Population characteristics
Of the 354 consecutive high risk patients who were screened for TAVI between October 2006 and June 2010, 201 patients underwent TAVI and represent the study population. Mean age was 81 ± 8 years; patients were at high operative risk as attested by the logistic EuroSCORE (28% ± 15). Only nine patients had a logistic EuroSCORE < 20%: 1 with previous CABG was selected for TAVI because of a history of mediastinal radiotherapy; and eight without previous CABG were selected because of severe respiratory failure (n = 4), cirrhosis (n = 1), myeloproliferative syndrome (n = 1), severe cyphoscoliosis (n = 1) or short-term scheduled neurosurgical intervention (n = 1). Associated comorbidities were common as assessed by the Charlson comorbidity index [9] (6.2 ± 2.7). The prevalence of coronary artery disease (CAD) was high (57% of the population) and 54 patients (27%) had a history of CABG.
For those 54 patients, CABG was performed 12.8 ± 6.8 years (1-27 years) before TAVI. Four patients had a history of redo CABG. Overall, patients received a mean of 2.6 grafts: 27 patients (51%) had a 3-vessel revascularization, 23 patients (43%) a 2-vessel and three patients (6%) a single-vessel revascularization. Forty-nine patients (81%) had at least one mammary artery graft; nine patients (17%) had a pure internal mammary artery revascularization whereas four patients (7.5%) received only venous grafts. On screening angiogram, 56 out of 63 mammary grafts (89%) and 50 out of 76 (66%) saphenous grafts were patent (i.e. a mean of 2.1 patent graft per patient). Three patients underwent percutaneous coronary intervention (PCI) of a graft [one left internal mammary artery (LIMA) and two saphenous grafts] before TAVI as a staged procedure (respectively 5, 1.5, and 1 months before TAVI).
Comparison of the clinical and echographic characteristics of patients with and without previous CABG is presented in Tables 1 and 2 . Patients with previous CABG were younger and were more frequently men, had more frequent carotid stenoses, and previous MI. Overall, the Charlson comorbidity index did not differ between the two groups.
TAVI procedure
Among the 201 patients who underwent TAVI, a transarterial approach was performed in 140 patients (70%) including 131 transfemoral, six left subclavian and three retroperitoneal transiliac; a transapical approach was performed in 61 patients (30%) ( Table 3 ). In patients with patent LIMA graft, left subclavian approach, even if it has been described to be a safe approach [10] was avoided. However, two patients with patent LIMA underwent left subclavian TAVI as left subclavian artery was the only possible approach. They did not present any ischaemic complications. Transapical approach was more frequently performed in patients with previous CABG (Table 3 ). The proportions of Edwards Sapien and Medtronic Core Valve prosthesis used were similar in both groups.
Thirty-day outcome
Thirty-day outcome is presented in Table 4 . Implantation success rate was high and similar in both groups (98%). Three deaths Results are expressed as n (%). 
Mid-term outcome
Mid-term vital status was available for all patients. Mean follow up was 7 ± 9 months [1 to 37]. Eighteen deaths were reported after discharge: two in the group of patients with previous CABG and 16 in the group of patients without. Causes of deaths are detailed in Table 5 . Overall, 37 deaths occurred including six deaths in patients with previous CABG vs. 31 in the group without, resulting in a 2-year survival rate of 80.0 ± 7.7% in patients with previous CABG vs. 65.7 ± 6.2% in patients without CABG, P = 0.12 ( Fig. 1) .
In univariate analysis, variables associated with increased mid-term mortality (P < 0.2) were older age, prior myocardial infarction, congestive heart failure, absence of prior CABG, transapical approach (mainly due to early mortality) and early experience. Multivariate analysis identified three predictive factors of mid-term mortality: transapical vs. transarterial approach, early experience and absence of prior CABG (Table 6 ). Conversely, Charlson comorbidity index was not associated with survival (P = 0.26).
DISCUSSION
This study is to the best of our knowledge the first to focus specifically on the impact of previous CABG on outcome after TAVI. It suggests that a history of CABG does not adversely impact early outcome or mid-term mortality after TAVI.
Risk of AVR after previous CABG
Redo AVR in patients with severe AS and a history of CABG is a common but challenging clinical situation [1-4, 11, 12] . A high mortality for this surgery was initially reported ranging from 10 to more than 20% [1, 2] . Even if more recent series report a lower mortality rate [3, 4] , this situation still raises specific technical issues in addition to the risk related to the redo. The first one is the risk of damaging a right internal mammary artery anastomosed to the LAD crossing the line of sternotomy. A pure internal mammary artery CABG based on the in situ left IMA may, however, minimize this risk [12, 13] . The presence of multiple venous grafts can make the redo aortotomy tricky by limiting access to the proximal ascending aorta. This, combined with severe graft disease, carries the risk of distal embolization into the coronary arteries during the dissection of venous grafts. Adequate myocardial protection and maintaining cardiac arrest with patent grafts, particularly the internal mammary arteries, is another issue. Finally, the retrograde flow through the coronary ostia may further complicate AVR by flooding the surgical field.
TAVI after previous cardiac surgery
TAVI has demonstrated good early and mid-term outcomes in high-risk patients [14] [15] [16] [17] . The theoretical interest of TAVI in patients with previous CABG is to offer an alternative approach to sternotomy, eliminating the technical issues described above. Small series have described interesting results in patients with previous cardiac surgery: Webb et al. report good outcomes after transcatheter valve in valve implantation for the management of 24 patients with bioprosthetic valve failure including 10 aortic valves [18] . Drews et al. [19] describe good outcomes in 40 transapical TAVI after previous heart surgery, including both aortic and mitral valve surgery as well as 33 CABG. Our series is 
Outcomes after TAVI in patients with previous CABG
The good outcomes reported here in patients with previous CABG are in agreement with other large series. In the PARTNER trial [16] the subgroup of patients with prior CABG or PCI demonstrated a significant benefit from TAVI over medical treatment similar to those patients without CABG. In the multicentre Canadian registry [20] , there was a similar mortality rate in the groups with and without CABG. Conversely, Dewey et al. described a higher mortality in patients with concomitant CAD (including patients with previous CABG or PCI) 20 . However, data regarding the specific subgroup of patients with previous CABG are not available.
The multivariate analysis identified a history of CABG as an independent predictive factor of better mid-term survival. This apparently contradictory association may be due to residual confounding bias which is not fully controlled by the multivariate analysis. Since previous CABG is in itself an important factor leading to favour TAVI over conventional AVR, patients with previous CABG are younger and may be at lower risk of late mortality even if there are no significant differences in most comorbidities as shown in Table 1 . Even if the multivariate analysis limits the impact of differences in patient characteristics, it does not allow for controlling the impact of all potential confounding factors. Of note, the logistic EuroSCORE was higher in patients with previous CABG but must be interpreted cautiously to compare the procedural risk of both groups as it includes CABG history in its calculation.
Limitations
Our series presents several limitations. The main limitation is its observational nature. Definite conclusions could come only from a randomized trial. The sample size in a monocentric experience led to a limited statistical power. However, it provides homogeneous assessment of high risk patients. Further analyses of larger multicentre series would be of great interest [17, 20] . Finally, we did not strictly comply to the Valve Academic Research Consortium definitions [21] for the adjudication of outcome. This is explained by the fact that data were prospectively collected and events adjudicated since 2006.
CONCLUSION
The findings from this monocentric retrospective observational study suggest that a history of CABG does not adversely impact outcomes in patients undergoing TAVI. If confirmed by larger prospective series and ideally by a randomized trial comparing CABG vs. redo surgery, this observation might lead the heart team to consider TAVI as an attractive option in the population of high risk patients with AS and previous CABG. 
